RANBAXY’S BASE BUSINESS ACROSS GEOGRAPHIES CONTINUES TO DELIVER STRONG RESULTS

Printer-friendly versionPDF version

Q2 FY 2011 Sales $461 Mn, EBITDA: $48 Mn, PAT $54 Mn.
H1 FY 2011 Sales $935 Mn, EBITDA: $143 Mn, PAT $122 Mn.

Gurgaon, India/ Cluj, Romania, August 5, 2011

The Board of Directors of Ranbaxy Laboratories Limited (RLL, NSE: RANBAXY, BSE: 500359), at their meeting held today, took on record the unaudited results for the Quarter ended and Half year ended June 30, 2011 (the “Q2’11” and “H1’11” respectively) under Indian GAAP.

Key Financial Highlights

Financial Performance for the quarter ended June 30, 2011 (Q2’11)

Revenue and profitability numbers for Quarter 2, 2010 and 2011 and for Half Year (“H1’11”) ended June 30, 2011 are not strictly comparable, because of the varying FTF contributions to the overall results.

Financial Performance for the half year ended June 30, 2011 (H1’11)

Commenting on the business results for the quarter, Mr. Arun Sawhney, Managing Director, Ranbaxy, said, “We have consciously worked towards strengthening our base business on the one hand and successfully delivering on multiple first to file opportunities on the other.”

Key Highlights/Developments

Business

Regulatory, Research & Development

Global Sales

Consolidated sales for the Quarter were $461 Mn (Rs. 20,593 Mn) as compared to $456 Mn (Rs. 20,953 Mn) in the corresponding quarter, of the previous year. Emerging markets contributed $261 Mn, accounting for 57% of total sales. Developed markets recorded $157 Mn of sales and contributed 34% to total sales for the Company. API and others accounted for the rest of the revenue for the Quarter.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company’s commitment to increase penetration and improve access to medicines, across the globe.

News Source : RANBAXY’S BASE BUSINESS ACROSS GEOGRAPHIES CONTINUES TO DELIVER STRONG RESULTS